

Appendix E (continued)
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
(b) (6)	250 mcg mRNA-1273 (18-55 years)	MALE	51	-1	-11	Creatinine (mg/dL)	1.01	N/A	N/A	N/A	N/A
	250 mcg mRNA-1273 (18-55 years)	MALE	51	1	1	Creatinine (mg/dL)	1.12	N/A	N/A	N/A	N/A
	250 mcg mRNA-1273 (18-55 years)	MALE	51	8	7	Creatinine (mg/dL)	1.16	N/A	N/A	N/A	N/A
	250 mcg mRNA-1273 (18-55 years)	MALE	51	29	29	Creatinine (mg/dL)	1.09	N/A	N/A	N/A	N/A
	250 mcg mRNA-1273 (18-55 years)	MALE	51	36	35	Creatinine (mg/dL)	1.00	N/A	N/A	N/A	N/A
	250 mcg mRNA-1273 (18-55 years)	MALE	51	-1	-11	Hemoglobin (g/dL)	16.3	N/A	N/A	N/A	N/A
	250 mcg mRNA-1273 (18-55 years)	MALE	51	1	1	Hemoglobin (g/dL)	16.5	N/A	N/A	N/A	N/A
	250 mcg mRNA-1273 (18-55 years)	MALE	51	8	7	Hemoglobin (g/dL)	15.1 (Mild)	NOT RELATED	Due to study procedure - phlebotomy	NC- DOSE NOT CHANGED	No

Appendix E (continued)
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
(b) (6)	250 mcg mRNA-1273 (18-55 years)	MALE	51	29	29	Hemoglobin (g/dL)	15.4 (Mild)	NOT RELATED	Grade 1 Due to study procedure phlebotomy	NC- DOSE NOT CHANGED	No
	250 mcg mRNA-1273 (18-55 years)	MALE	51	36	35	Hemoglobin (g/dL)	14.7 (Moderate)	RELATED	N/A	N/A	N/A
	250 mcg mRNA-1273 (18-55 years)	MALE	51	-1	-11	PT (seconds)	10.0	N/A	N/A	N/A	N/A
	250 mcg mRNA-1273 (18-55 years)	MALE	51	-1	-11	PTT (seconds)	30	N/A	N/A	N/A	N/A
	250 mcg mRNA-1273 (18-55 years)	MALE	51	-1	-11	Platelets (10 ³ /uL)	267	N/A	N/A	N/A	N/A
	250 mcg mRNA-1273 (18-55 years)	MALE	51	1	1	Platelets (10 ³ /uL)	266	N/A	N/A	N/A	N/A
	250 mcg mRNA-1273 (18-55 years)	MALE	51	8	7	Platelets (10 ³ /uL)	266	N/A	N/A	N/A	N/A
	250 mcg mRNA-1273 (18-55 years)	MALE	51	29	29	Platelets (10 ³ /uL)	241	N/A	N/A	N/A	N/A
	250 mcg mRNA-1273 (18-55 years)	MALE	51	36	35	Platelets (10 ³ /uL)	253	N/A	N/A	N/A	N/A

Report Date: 02JUN2020
Data Cutoff Date: 25MAY2020

Appendix E (continued)
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
(b) (6)	250 mcg mRNA-1273 (18-55 years)	MALE	51	-1	-11	Serum Lipase (U/L)	48.0	N/A	N/A	N/A	N/A
	250 mcg mRNA-1273 (18-55 years)	MALE	51	1	1	Serum Lipase (U/L)	62.0	N/A	N/A	N/A	N/A
	250 mcg mRNA-1273 (18-55 years)	MALE	51	8	7	Serum Lipase (U/L)	41.0	N/A	N/A	N/A	N/A
	250 mcg mRNA-1273 (18-55 years)	MALE	51	29	29	Serum Lipase (U/L)	39.0	N/A	N/A	N/A	N/A
	250 mcg mRNA-1273 (18-55 years)	MALE	51	36	35	Serum Lipase (U/L)	112.0	N/A	N/A	N/A	N/A
	250 mcg mRNA-1273 (18-55 years)	MALE	51	-1	-11	Total Bilirubin (mg/dL)	0.7	N/A	N/A	N/A	N/A
	250 mcg mRNA-1273 (18-55 years)	MALE	51	1	1	Total Bilirubin (mg/dL)	0.8	N/A	N/A	N/A	N/A
	250 mcg mRNA-1273 (18-55 years)	MALE	51	8	7	Total Bilirubin (mg/dL)	0.5	N/A	N/A	N/A	N/A
	250 mcg mRNA-1273 (18-55 years)	MALE	51	29	29	Total Bilirubin (mg/dL)	0.6	N/A	N/A	N/A	N/A

Appendix E (continued)
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
(b) (6)	250 mcg mRNA-1273 (18-55 years)	MALE	51	36	35	Total Bilirubin (mg/dL)	0.5	N/A	N/A	N/A	N/A
	250 mcg mRNA-1273 (18-55 years)	MALE	51	-1	-11	WBC (10 ³ /uL)	5.8	N/A	N/A	N/A	N/A
	250 mcg mRNA-1273 (18-55 years)	MALE	51	1	1	WBC (10 ³ /uL)	5.5	N/A	N/A	N/A	N/A
	250 mcg mRNA-1273 (18-55 years)	MALE	51	8	7	WBC (10 ³ /uL)	5.4	N/A	N/A	N/A	N/A
	250 mcg mRNA-1273 (18-55 years)	MALE	51	29	29	WBC (10 ³ /uL)	6.2	N/A	N/A	N/A	N/A
	250 mcg mRNA-1273 (18-55 years)	MALE	51	36	35	WBC (10 ³ /uL)	6.3	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (56-70 years)	MALE	69	-1	-7	Alanine Aminotransferase (U/L)	18	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (56-70 years)	MALE	69	1	1	Alanine Aminotransferase (U/L)	19	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (56-70 years)	MALE	69	8	7	Alanine Aminotransferase (U/L)	17	N/A	N/A	N/A	N/A

Appendix E (continued)
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
(b) (6)	100 mcg mRNA-1273 (56-70 years)	MALE	67	29	30	Total Bilirubin (mg/dL)	0.5	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (56-70 years)	MALE	67	-1	-5	WBC (10 ³ /uL)	6.3	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (56-70 years)	MALE	67	1	1	WBC (10 ³ /uL)	6.7	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (56-70 years)	MALE	67	8	9	WBC (10 ³ /uL)	6.7	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (56-70 years)	MALE	67	29	30	WBC (10 ³ /uL)	5.6	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (56-70 years)	FEMALE	65	-1	-5	Alanine Aminotransferase (U/L)	25	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (56-70 years)	FEMALE	65	1	1	Alanine Aminotransferase (U/L)	22	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (56-70 years)	FEMALE	65	8	8	Alanine Aminotransferase (U/L)	15	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (56-70 years)	FEMALE	65	29	29	Alanine Aminotransferase (U/L)	20	N/A	N/A	N/A	N/A

Appendix E (continued)
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
(b) (6)	25 mcg mRNA-1273 (56-70 years)	FEMALE	65	-1	-5	Alkaline Phosphatase (U/L)	71	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (56-70 years)	FEMALE	65	1	1	Alkaline Phosphatase (U/L)	72	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (56-70 years)	FEMALE	65	8	8	Alkaline Phosphatase (U/L)	72	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (56-70 years)	FEMALE	65	29	29	Alkaline Phosphatase (U/L)	78	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (56-70 years)	FEMALE	65	-1	-5	Aspartate Aminotransferase (U/L)	18	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (56-70 years)	FEMALE	65	1	1	Aspartate Aminotransferase (U/L)	18	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (56-70 years)	FEMALE	65	8	8	Aspartate Aminotransferase (U/L)	13	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (56-70 years)	FEMALE	65	29	29	Aspartate Aminotransferase (U/L)	13	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (56-70 years)	FEMALE	65	-1	-5	Creatinine (mg/dL)	0.64	N/A	N/A	N/A	N/A

Appendix E (continued)
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
(b) (6)	25 mcg mRNA-1273 (56-70 years)	FEMALE	65	1	1	Creatinine (mg/dL)	0.73	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (56-70 years)	FEMALE	65	8	8	Creatinine (mg/dL)	0.69	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (56-70 years)	FEMALE	65	29	29	Creatinine (mg/dL)	0.70	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (56-70 years)	FEMALE	65	-1	-5	Hemoglobin (g/dL)	14.5	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (56-70 years)	FEMALE	65	1	1	Hemoglobin (g/dL)	14.6	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (56-70 years)	FEMALE	65	8	8	Hemoglobin (g/dL)	13.5 (Mild)	NOT RELATED	Grade 1 Due to study procedure phlebotomy	NC- DOSE NOT CHANGED	No
	25 mcg mRNA-1273 (56-70 years)	FEMALE	65	29	29	Hemoglobin (g/dL)	13.9 (Mild)	NOT RELATED	Grade 1 Due to study procedure phlebotomy	NA- NOT APPLICABLE	No
	25 mcg mRNA-1273 (56-70 years)	FEMALE	65	-1	-5	PT (seconds)	10.2	N/A	N/A	N/A	N/A

Appendix E (continued)
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
(b) (6)	25 mcg mRNA-1273 (56-70 years)	FEMALE	65	-1	-5	Total Bilirubin (mg/dL)	0.5	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (56-70 years)	FEMALE	65	1	1	Total Bilirubin (mg/dL)	0.7	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (56-70 years)	FEMALE	65	8	8	Total Bilirubin (mg/dL)	0.6	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (56-70 years)	FEMALE	65	29	29	Total Bilirubin (mg/dL)	0.5	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (56-70 years)	FEMALE	65	-1	-5	WBC (10 ³ /uL)	6.1	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (56-70 years)	FEMALE	65	1	1	WBC (10 ³ /uL)	5.8	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (56-70 years)	FEMALE	65	8	8	WBC (10 ³ /uL)	5.5	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (56-70 years)	FEMALE	65	29	29	WBC (10 ³ /uL)	6.0	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (56-70 years)	FEMALE	68	-1	-5	Alanine Aminotransferase (U/L)	12	N/A	N/A	N/A	N/A

Appendix E (continued)
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
(b) (6)	25 mcg mRNA-1273 (56-70 years)	FEMALE	68	8	8	Aspartate Aminotransferase (U/L)	16	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (56-70 years)	FEMALE	68	29	29	Aspartate Aminotransferase (U/L)	15	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (56-70 years)	FEMALE	68	-1	-5	Creatinine (mg/dL)	0.75	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (56-70 years)	FEMALE	68	1	1	Creatinine (mg/dL)	0.77	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (56-70 years)	FEMALE	68	8	8	Creatinine (mg/dL)	0.80	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (56-70 years)	FEMALE	68	29	29	Creatinine (mg/dL)	0.77	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (56-70 years)	FEMALE	68	-1	-5	Hemoglobin (g/dL)	13.3	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (56-70 years)	FEMALE	68	1	1	Hemoglobin (g/dL)	12.9	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (56-70 years)	FEMALE	68	8	8	Hemoglobin (g/dL)	11.7 (Mild)	NOT RELATED	Grade 1 Due to study procedure phlebotomy	NC- DOSE NOT CHANGED	No

Appendix E (continued)
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
(b) (6)	25 mcg mRNA-1273 (56-70 years)	FEMALE	68	29	29	Hemoglobin (g/dL)	12.1 (Mild)	NOT RELATED	Grade 1 Due to study procedure phlebotomy	NA-NOT APPLICABLE	No
	25 mcg mRNA-1273 (56-70 years)	FEMALE	68	-1	-5	PT (seconds)	10.2	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (56-70 years)	FEMALE	68	-1	-5	PTT (seconds)	29	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (56-70 years)	FEMALE	68	-1	-5	Platelets (10 ³ /uL)	209	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (56-70 years)	FEMALE	68	1	1	Platelets (10 ³ /uL)	192	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (56-70 years)	FEMALE	68	8	8	Platelets (10 ³ /uL)	189	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (56-70 years)	FEMALE	68	29	29	Platelets (10 ³ /uL)	185	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (56-70 years)	FEMALE	68	-1	-5	Serum Lipase (U/L)	14.0	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (56-70 years)	FEMALE	68	1	1	Serum Lipase (U/L)	9.0	N/A	N/A	N/A	N/A

Report Date: 02JUN2020
Data Cutoff Date: 25MAY2020

Appendix E (continued)
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
(b) (6)	25 mcg mRNA-1273 (56-70 years)	FEMALE	68	8	8	Serum Lipase (U/L)	12.0	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (56-70 years)	FEMALE	68	29	29	Serum Lipase (U/L)	16.0	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (56-70 years)	FEMALE	68	-1	-5	Total Bilirubin (mg/dL)	0.5	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (56-70 years)	FEMALE	68	1	1	Total Bilirubin (mg/dL)	1.1	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (56-70 years)	FEMALE	68	8	8	Total Bilirubin (mg/dL)	0.6	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (56-70 years)	FEMALE	68	29	29	Total Bilirubin (mg/dL)	0.4	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (56-70 years)	FEMALE	68	-1	-5	WBC (10 ³ /uL)	6.5	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (56-70 years)	FEMALE	68	1	1	WBC (10 ³ /uL)	4.2	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (56-70 years)	FEMALE	68	8	8	WBC (10 ³ /uL)	4.6	N/A	N/A	N/A	N/A

Appendix E (continued)
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
(b) (6)	25 mcg mRNA-1273 (56-70 years)	FEMALE	68	29	29	WBC (10 ³ /uL)	4.4	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (56-70 years)	FEMALE	68	-1	-5	Alanine Aminotransferase (U/L)	24	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (56-70 years)	FEMALE	68	1	1	Alanine Aminotransferase (U/L)	18	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (56-70 years)	FEMALE	68	8	8	Alanine Aminotransferase (U/L)	18	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (56-70 years)	FEMALE	68	29	29	Alanine Aminotransferase (U/L)	24	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (56-70 years)	FEMALE	68	-1	-5	Alkaline Phosphatase (U/L)	105	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (56-70 years)	FEMALE	68	1	1	Alkaline Phosphatase (U/L)	103	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (56-70 years)	FEMALE	68	8	8	Alkaline Phosphatase (U/L)	104	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (56-70 years)	FEMALE	68	29	29	Alkaline Phosphatase (U/L)	102	N/A	N/A	N/A	N/A

Appendix E (continued)
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
(b) (6)	25 mcg mRNA-1273 (56-70 years)	FEMALE	68	-1	-5	Aspartate Aminotransferase (U/L)	21	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (56-70 years)	FEMALE	68	1	1	Aspartate Aminotransferase (U/L)	19	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (56-70 years)	FEMALE	68	8	8	Aspartate Aminotransferase (U/L)	24	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (56-70 years)	FEMALE	68	29	29	Aspartate Aminotransferase (U/L)	22	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (56-70 years)	FEMALE	68	-1	-5	Creatinine (mg/dL)	0.74	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (56-70 years)	FEMALE	68	1	1	Creatinine (mg/dL)	0.66	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (56-70 years)	FEMALE	68	8	8	Creatinine (mg/dL)	0.64	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (56-70 years)	FEMALE	68	29	29	Creatinine (mg/dL)	0.80	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (56-70 years)	FEMALE	68	-1	-5	Hemoglobin (g/dL)	14.6	N/A	N/A	N/A	N/A

Appendix E (continued)
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
(b) (6)	25 mcg mRNA-1273 (56-70 years)	FEMALE	68	1	1	Hemoglobin (g/dL)	14.8	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (56-70 years)	FEMALE	68	8	8	Hemoglobin (g/dL)	14.8	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (56-70 years)	FEMALE	68	29	29	Hemoglobin (g/dL)	14.7 (Mild)	NOT RELATED	Grade 1 Due to study procedure phlebotomy	NA- NOT APPLICABLE	No
	25 mcg mRNA-1273 (56-70 years)	FEMALE	68	-1	-5	PT (seconds)	10.0	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (56-70 years)	FEMALE	68	-1	-5	PTT (seconds)	29	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (56-70 years)	FEMALE	68	-1	-5	Platelets (10 ³ /uL)	320	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (56-70 years)	FEMALE	68	1	1	Platelets (10 ³ /uL)	332	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (56-70 years)	FEMALE	68	8	8	Platelets (10 ³ /uL)	337	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (56-70 years)	FEMALE	68	29	29	Platelets (10 ³ /uL)	352	N/A	N/A	N/A	N/A

Report Date: 02JUN2020
Data Cutoff Date: 25MAY2020

Appendix E (continued)
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
(b) (6)	25 mcg mRNA-1273 (56-70 years)	FEMALE	69	8	8	Alkaline Phosphatase (U/L)	68	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (56-70 years)	FEMALE	69	29	30	Alkaline Phosphatase (U/L)	66	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (56-70 years)	FEMALE	69	-1	-5	Aspartate Aminotransferase (U/L)	15	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (56-70 years)	FEMALE	69	1	1	Aspartate Aminotransferase (U/L)	25	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (56-70 years)	FEMALE	69	8	8	Aspartate Aminotransferase (U/L)	16	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (56-70 years)	FEMALE	69	29	30	Aspartate Aminotransferase (U/L)	17	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (56-70 years)	FEMALE	69	-1	-5	Creatinine (mg/dL)	0.77	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (56-70 years)	FEMALE	69	1	1	Creatinine (mg/dL)	0.93	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (56-70 years)	FEMALE	69	8	8	Creatinine (mg/dL)	0.92	N/A	N/A	N/A	N/A

Appendix E (continued)
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
(b) (6)	25 mcg mRNA-1273 (56-70 years)	FEMALE	69	29	30	Creatinine (mg/dL)	0.89	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (56-70 years)	FEMALE	69	-1	-5	Hemoglobin (g/dL)	14.3	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (56-70 years)	FEMALE	69	1	1	Hemoglobin (g/dL)	14.7	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (56-70 years)	FEMALE	69	8	8	Hemoglobin (g/dL)	14.3 (Mild)	NOT RELATED	Grade 1 Due to study procedure phlebotomy	NC- DOSE NOT CHANGED	No
	25 mcg mRNA-1273 (56-70 years)	FEMALE	69	29	30	Hemoglobin (g/dL)	13.1 (Moderate)	RELATED	N/A	N/A	N/A
	25 mcg mRNA-1273 (56-70 years)	FEMALE	69	-1	-5	PT (seconds)	10.6	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (56-70 years)	FEMALE	69	-1	-5	PTT (seconds)	28	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (56-70 years)	FEMALE	69	-1	-5	Platelets (10 ³ /uL)	206	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (56-70 years)	FEMALE	69	1	1	Platelets (10 ³ /uL)	221	N/A	N/A	N/A	N/A

Report Date: 02JUN2020
Data Cutoff Date: 25MAY2020

Appendix E (continued)
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
(b) (6)	25 mcg mRNA-1273 (56-70 years)	FEMALE	69	8	8	Platelets (10 ³ /uL)	217	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (56-70 years)	FEMALE	69	29	30	Platelets (10 ³ /uL)	221	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (56-70 years)	FEMALE	69	-1	-5	Serum Lipase (U/L)	18.0	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (56-70 years)	FEMALE	69	1	1	Serum Lipase (U/L)	15.0	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (56-70 years)	FEMALE	69	8	8	Serum Lipase (U/L)	15.0	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (56-70 years)	FEMALE	69	29	30	Serum Lipase (U/L)	21.0	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (56-70 years)	FEMALE	69	-1	-5	Total Bilirubin (mg/dL)	0.5	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (56-70 years)	FEMALE	69	1	1	Total Bilirubin (mg/dL)	0.8	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (56-70 years)	FEMALE	69	8	8	Total Bilirubin (mg/dL)	0.6	N/A	N/A	N/A	N/A

Appendix E (continued)
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
(b) (6)	25 mcg mRNA-1273 (56-70 years)	FEMALE	69	29	30	Total Bilirubin (mg/dL)	0.7	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (56-70 years)	FEMALE	69	-1	-5	WBC (10 ³ /uL)	5.3	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (56-70 years)	FEMALE	69	1	1	WBC (10 ³ /uL)	5.3	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (56-70 years)	FEMALE	69	8	8	WBC (10 ³ /uL)	6.4	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (56-70 years)	FEMALE	69	29	30	WBC (10 ³ /uL)	6.0	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (56-70 years)	FEMALE	64	-1	-5	Alanine Aminotransferase (U/L)	15	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (56-70 years)	FEMALE	64	1	1	Alanine Aminotransferase (U/L)	15	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (56-70 years)	FEMALE	64	8	7	Alanine Aminotransferase (U/L)	14	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (56-70 years)	FEMALE	64	29	28	Alanine Aminotransferase (U/L)	20	N/A	N/A	N/A	N/A

Appendix E (continued)
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
(b) (6)	100 mcg mRNA-1273 (56-70 years)	FEMALE	64	-1	-5	Alkaline Phosphatase (U/L)	66	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (56-70 years)	FEMALE	64	1	1	Alkaline Phosphatase (U/L)	68	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (56-70 years)	FEMALE	64	8	7	Alkaline Phosphatase (U/L)	71	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (56-70 years)	FEMALE	64	29	28	Alkaline Phosphatase (U/L)	67	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (56-70 years)	FEMALE	64	-1	-5	Aspartate Aminotransferase (U/L)	20	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (56-70 years)	FEMALE	64	1	1	Aspartate Aminotransferase (U/L)	21	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (56-70 years)	FEMALE	64	8	7	Aspartate Aminotransferase (U/L)	20	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (56-70 years)	FEMALE	64	29	28	Aspartate Aminotransferase (U/L)	22	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (56-70 years)	FEMALE	64	-1	-5	Creatinine (mg/dL)	0.84	N/A	N/A	N/A	N/A

Appendix E (continued)
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
(b) (6)	100 mcg mRNA-1273 (56-70 years)	FEMALE	64	1	1	Creatinine (mg/dL)	0.85	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (56-70 years)	FEMALE	64	8	7	Creatinine (mg/dL)	0.85	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (56-70 years)	FEMALE	64	29	28	Creatinine (mg/dL)	0.82	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (56-70 years)	FEMALE	64	-1	-5	Hemoglobin (g/dL)	13.7	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (56-70 years)	FEMALE	64	1	1	Hemoglobin (g/dL)	14.4	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (56-70 years)	FEMALE	64	8	7	Hemoglobin (g/dL)	13.6 (Mild)	NOT RELATED	Grade 1 Due to study procedure phlebotomy	NC- DOSE NOT CHANGED	No
	100 mcg mRNA-1273 (56-70 years)	FEMALE	64	29	28	Hemoglobin (g/dL)	12.9 (Mild)	NOT RELATED	Grade 1 Due to study procedure phlebotomy	NA- NOT APPLICABLE	No
	100 mcg mRNA-1273 (56-70 years)	FEMALE	64	-1	-5	PT (seconds)	10.3	N/A	N/A	N/A	N/A

Appendix E (continued)
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
(b) (6)	100 mcg mRNA-1273 (56-70 years)	FEMALE	64	-1	-5	PTT (seconds)	21	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (56-70 years)	FEMALE	64	-1	-5	Platelets (10 ³ /uL)	216	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (56-70 years)	FEMALE	64	1	1	Platelets (10 ³ /uL)	199	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (56-70 years)	FEMALE	64	8	7	Platelets (10 ³ /uL)	216	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (56-70 years)	FEMALE	64	29	28	Platelets (10 ³ /uL)	202	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (56-70 years)	FEMALE	64	-1	-5	Serum Lipase (U/L)	57.0	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (56-70 years)	FEMALE	64	1	1	Serum Lipase (U/L)	50.0	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (56-70 years)	FEMALE	64	8	7	Serum Lipase (U/L)	50.0	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (56-70 years)	FEMALE	64	29	28	Serum Lipase (U/L)	62.0	N/A	N/A	N/A	N/A

Appendix E (continued)
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
(b) (6)	100 mcg mRNA-1273 (56-70 years)	FEMALE	64	-1	-5	Total Bilirubin (mg/dL)	0.5	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (56-70 years)	FEMALE	64	1	1	Total Bilirubin (mg/dL)	0.5	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (56-70 years)	FEMALE	64	8	7	Total Bilirubin (mg/dL)	0.4	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (56-70 years)	FEMALE	64	29	28	Total Bilirubin (mg/dL)	0.4	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (56-70 years)	FEMALE	64	-1	-5	WBC (10 ³ /uL)	5.6	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (56-70 years)	FEMALE	64	1	1	WBC (10 ³ /uL)	4.6	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (56-70 years)	FEMALE	64	8	7	WBC (10 ³ /uL)	5.9	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (56-70 years)	FEMALE	64	29	28	WBC (10 ³ /uL)	5.2	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (56-70 years)	FEMALE	63	-1	-5	Alanine Aminotransferase (U/L)	11	N/A	N/A	N/A	N/A

Appendix E (continued)
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
(b) (6)	100 mcg mRNA-1273 (56-70 years)	FEMALE	63	8	8	Aspartate Aminotransferase (U/L)	15	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (56-70 years)	FEMALE	63	29	29	Aspartate Aminotransferase (U/L)	18	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (56-70 years)	FEMALE	63	-1	-5	Creatinine (mg/dL)	0.79	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (56-70 years)	FEMALE	63	1	1	Creatinine (mg/dL)	0.73	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (56-70 years)	FEMALE	63	8	8	Creatinine (mg/dL)	0.87	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (56-70 years)	FEMALE	63	29	29	Creatinine (mg/dL)	0.75	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (56-70 years)	FEMALE	63	-1	-5	Hemoglobin (g/dL)	13.8	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (56-70 years)	FEMALE	63	1	1	Hemoglobin (g/dL)	13.3	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (56-70 years)	FEMALE	63	8	8	Hemoglobin (g/dL)	12.5 (Mild)	NOT RELATED	study procedures - phlebotomy	NC- DOSE NOT CHANGED	No

Appendix E (continued)
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
(b) (6)	100 mcg mRNA-1273 (56-70 years)	FEMALE	63	29	29	Hemoglobin (g/dL)	13.0 (Mild)	NOT RELATED	Grade 1, due to phlebotomy	NA-NOT APPLICABLE	No
	100 mcg mRNA-1273 (56-70 years)	FEMALE	63	-1	-5	PT (seconds)	10.3	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (56-70 years)	FEMALE	63	-1	-5	PTT (seconds)	31	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (56-70 years)	FEMALE	63	-1	-5	Platelets (10 ³ /uL)	371	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (56-70 years)	FEMALE	63	1	1	Platelets (10 ³ /uL)	355	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (56-70 years)	FEMALE	63	8	8	Platelets (10 ³ /uL)	370	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (56-70 years)	FEMALE	63	29	29	Platelets (10 ³ /uL)	352	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (56-70 years)	FEMALE	63	-1	-5	Serum Lipase (U/L)	38.0	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (56-70 years)	FEMALE	63	1	1	Serum Lipase (U/L)	38.0	N/A	N/A	N/A	N/A

Appendix E (continued)
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
(b) (6)	100 mcg mRNA-1273 (56-70 years)	FEMALE	63	29	29	WBC (10 ³ /uL)	7.6	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (56-70 years)	MALE	66	-1	-5	Alanine Aminotransferase (U/L)	12	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (56-70 years)	MALE	66	1	1	Alanine Aminotransferase (U/L)	14	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (56-70 years)	MALE	66	8	8	Alanine Aminotransferase (U/L)	15	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (56-70 years)	MALE	66	29	29	Alanine Aminotransferase (U/L)	12	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (56-70 years)	MALE	66	-1	-5	Alkaline Phosphatase (U/L)	79	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (56-70 years)	MALE	66	1	1	Alkaline Phosphatase (U/L)	82	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (56-70 years)	MALE	66	8	8	Alkaline Phosphatase (U/L)	79	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (56-70 years)	MALE	66	29	29	Alkaline Phosphatase (U/L)	67	N/A	N/A	N/A	N/A

Appendix E (continued)
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
(b) (6)	100 mcg mRNA-1273 (56-70 years)	MALE	66	1	1	Hemoglobin (g/dL)	15.7	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (56-70 years)	MALE	66	8	8	Hemoglobin (g/dL)	15.2 (Mild)	NOT RELATED	study procedure phlebotomy	NC- DOSE NOT CHANGED	No
	100 mcg mRNA-1273 (56-70 years)	MALE	66	29	29	Hemoglobin (g/dL)	14.8 (Mild)	NOT RELATED	Grade 1 Due to study procedure phlebotomy	NA- NOT APPLICABLE	No
	100 mcg mRNA-1273 (56-70 years)	MALE	66	-1	-5	PT (seconds)	10.3	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (56-70 years)	MALE	66	-1	-5	PTT (seconds)	28	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (56-70 years)	MALE	66	-1	-5	Platelets (10 ³ /uL)	267	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (56-70 years)	MALE	66	1	1	Platelets (10 ³ /uL)	267	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (56-70 years)	MALE	66	8	8	Platelets (10 ³ /uL)	256	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (56-70 years)	MALE	66	29	29	Platelets (10 ³ /uL)	250	N/A	N/A	N/A	N/A

Report Date: 02JUN2020
Data Cutoff Date: 25MAY2020

Appendix E (continued)
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
(b) (6)	100 mcg mRNA-1273 (56-70 years)	MALE	66	-1	-5	Serum Lipase (U/L)	48.0	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (56-70 years)	MALE	66	1	1	Serum Lipase (U/L)	56.0	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (56-70 years)	MALE	66	8	8	Serum Lipase (U/L)	65.0	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (56-70 years)	MALE	66	29	29	Serum Lipase (U/L)	48.0	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (56-70 years)	MALE	66	-1	-5	Total Bilirubin (mg/dL)	0.6	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (56-70 years)	MALE	66	1	1	Total Bilirubin (mg/dL)	0.7	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (56-70 years)	MALE	66	8	8	Total Bilirubin (mg/dL)	1.0	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (56-70 years)	MALE	66	29	29	Total Bilirubin (mg/dL)	1.2	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (56-70 years)	MALE	66	-1	-5	WBC (10 ³ /uL)	7.2	N/A	N/A	N/A	N/A

Appendix E (continued)
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
(b) (6)	100 mcg mRNA-1273 (56-70 years)	MALE	66	1	1	WBC (10 ³ /uL)	6.7	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (56-70 years)	MALE	66	8	8	WBC (10 ³ /uL)	5.5	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (56-70 years)	MALE	66	29	29	WBC (10 ³ /uL)	4.5	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (56-70 years)	FEMALE	60	-1	-3	Alanine Aminotransferase (U/L)	22	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (56-70 years)	FEMALE	60	1	1	Alanine Aminotransferase (U/L)	21	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (56-70 years)	FEMALE	60	8	9	Alanine Aminotransferase (U/L)	18	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (56-70 years)	FEMALE	60	29	30	Alanine Aminotransferase (U/L)	21	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (56-70 years)	FEMALE	60	-1	-3	Alkaline Phosphatase (U/L)	53	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (56-70 years)	FEMALE	60	1	1	Alkaline Phosphatase (U/L)	53	N/A	N/A	N/A	N/A

Appendix E (continued)
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
(b) (6)	25 mcg mRNA-1273 (56-70 years)	FEMALE	60	8	9	Alkaline Phosphatase (U/L)	54	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (56-70 years)	FEMALE	60	29	30	Alkaline Phosphatase (U/L)	47	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (56-70 years)	FEMALE	60	-1	-3	Aspartate Aminotransferase (U/L)	19	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (56-70 years)	FEMALE	60	1	1	Aspartate Aminotransferase (U/L)	22	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (56-70 years)	FEMALE	60	8	9	Aspartate Aminotransferase (U/L)	16	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (56-70 years)	FEMALE	60	29	30	Aspartate Aminotransferase (U/L)	23	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (56-70 years)	FEMALE	60	-1	-3	Creatinine (mg/dL)	0.65	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (56-70 years)	FEMALE	60	1	1	Creatinine (mg/dL)	0.66	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (56-70 years)	FEMALE	60	8	9	Creatinine (mg/dL)	0.68	N/A	N/A	N/A	N/A

Appendix E (continued)
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
(b) (6)	25 mcg mRNA-1273 (56-70 years)	FEMALE	60	29	30	Creatinine (mg/dL)	0.64	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (56-70 years)	FEMALE	60	-1	-3	Hemoglobin (g/dL)	13.8	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (56-70 years)	FEMALE	60	1	1	Hemoglobin (g/dL)	12.8	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (56-70 years)	FEMALE	60	8	9	Hemoglobin (g/dL)	12.6 (Mild)	NOT RELATED	study procedures -phlebotomy	NC- DOSE NOT CHANGED	No
	25 mcg mRNA-1273 (56-70 years)	FEMALE	60	29	30	Hemoglobin (g/dL)	12.2 (Mild)	NOT RELATED	Grade 1 Due to study procedure phlebotomy	NA- NOT APPLICABLE	No
	25 mcg mRNA-1273 (56-70 years)	FEMALE	60	-1	-3	PT (seconds)	10.3	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (56-70 years)	FEMALE	60	-1	-3	PTT (seconds)	30	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (56-70 years)	FEMALE	60	-1	-3	Platelets (10 ³ /uL)	361	N/A	N/A	N/A	N/A

Appendix E (continued)
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
(b) (6)	25 mcg mRNA-1273 (56-70 years)	FEMALE	60	8	9	Total Bilirubin (mg/dL)	0.5	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (56-70 years)	FEMALE	60	29	30	Total Bilirubin (mg/dL)	0.5	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (56-70 years)	FEMALE	60	-1	-3	WBC (10 ³ /uL)	5.2	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (56-70 years)	FEMALE	60	1	1	WBC (10 ³ /uL)	6.5	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (56-70 years)	FEMALE	60	8	9	WBC (10 ³ /uL)	6.2	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (56-70 years)	FEMALE	60	29	30	WBC (10 ³ /uL)	5.2	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (56-70 years)	FEMALE	68	-1	-7	Alanine Aminotransferase (U/L)	13	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (56-70 years)	FEMALE	68	1	1	Alanine Aminotransferase (U/L)	15	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (56-70 years)	FEMALE	68	8	7	Alanine Aminotransferase (U/L)	14	N/A	N/A	N/A	N/A

Appendix E (continued)
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
(b) (6)	100 mcg mRNA-1273 (56-70 years)	FEMALE	68	29	28	Alanine Aminotransferase (U/L)	18	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (56-70 years)	FEMALE	68	-1	-7	Alkaline Phosphatase (U/L)	44	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (56-70 years)	FEMALE	68	1	1	Alkaline Phosphatase (U/L)	42	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (56-70 years)	FEMALE	68	8	7	Alkaline Phosphatase (U/L)	49	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (56-70 years)	FEMALE	68	29	28	Alkaline Phosphatase (U/L)	44	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (56-70 years)	FEMALE	68	-1	-7	Aspartate Aminotransferase (U/L)	19	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (56-70 years)	FEMALE	68	1	1	Aspartate Aminotransferase (U/L)	18	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (56-70 years)	FEMALE	68	8	7	Aspartate Aminotransferase (U/L)	19	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (56-70 years)	FEMALE	68	29	28	Aspartate Aminotransferase (U/L)	23	N/A	N/A	N/A	N/A

Appendix E (continued)
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
(b) (6)	100 mcg mRNA-1273 (18-55 years)	MALE	22	36	35	Alkaline Phosphatase (U/L)	81	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (18-55 years)	MALE	22	-1	-4	Aspartate Aminotransferase (U/L)	19	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (18-55 years)	MALE	22	1	1	Aspartate Aminotransferase (U/L)	21	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (18-55 years)	MALE	22	8	9	Aspartate Aminotransferase (U/L)	21	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (18-55 years)	MALE	22	29	29	Aspartate Aminotransferase (U/L)	27	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (18-55 years)	MALE	22	36	35	Aspartate Aminotransferase (U/L)	26	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (18-55 years)	MALE	22	-1	-4	Creatinine (mg/dL)	0.82	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (18-55 years)	MALE	22	1	1	Creatinine (mg/dL)	0.92	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (18-55 years)	MALE	22	8	9	Creatinine (mg/dL)	0.95	N/A	N/A	N/A	N/A

Appendix E (continued)
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
(b) (6)	100 mcg mRNA-1273 (18-55 years)	MALE	22	29	29	Creatinine (mg/dL)	0.90	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (18-55 years)	MALE	22	36	35	Creatinine (mg/dL)	0.97	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (18-55 years)	MALE	22	-1	-4	Hemoglobin (g/dL)	14.3	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (18-55 years)	MALE	22	1	1	Hemoglobin (g/dL)	13.4 (Mild)	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (18-55 years)	MALE	22	8	9	Hemoglobin (g/dL)	14.4	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (18-55 years)	MALE	22	29	29	Hemoglobin (g/dL)	14.0	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (18-55 years)	MALE	22	36	35	Hemoglobin (g/dL)	14.3	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (18-55 years)	MALE	22	-1	-4	PT (seconds)	9.9	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (18-55 years)	MALE	22	-1	-4	PTT (seconds)	33	N/A	N/A	N/A	N/A

Appendix E (continued)
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
(b) (6)	100 mcg mRNA-1273 (18-55 years)	MALE	22	-1	-4	Platelets (10 ³ /uL)	367	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (18-55 years)	MALE	22	1	1	Platelets (10 ³ /uL)	321	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (18-55 years)	MALE	22	8	9	Platelets (10 ³ /uL)	379	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (18-55 years)	MALE	22	29	29	Platelets (10 ³ /uL)	367	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (18-55 years)	MALE	22	36	35	Platelets (10 ³ /uL)	345	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (18-55 years)	MALE	22	-1	-4	Serum Lipase (U/L)	27.0	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (18-55 years)	MALE	22	1	1	Serum Lipase (U/L)	24.0	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (18-55 years)	MALE	22	8	9	Serum Lipase (U/L)	24.0	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (18-55 years)	MALE	22	29	29	Serum Lipase (U/L)	33.0	N/A	N/A	N/A	N/A

Appendix E (continued)
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
(b) (6)	100 mcg mRNA-1273 (18-55 years)	MALE	22	29	29	WBC (10 ³ /uL)	6.3	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (18-55 years)	MALE	22	36	35	WBC (10 ³ /uL)	5.9	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (18-55 years)	MALE	34	-1	-4	Alanine Aminotransferase (U/L)	34	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (18-55 years)	MALE	34	1	1	Alanine Aminotransferase (U/L)	31	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (18-55 years)	MALE	34	8	8	Alanine Aminotransferase (U/L)	88 (Mild)	NOT RELATED	subject confirmed alcohol use	NC- DOSE NOT CHANGED	No
	100 mcg mRNA-1273 (18-55 years)	MALE	34	29	29	Alanine Aminotransferase (U/L)	39	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (18-55 years)	MALE	34	36	36	Alanine Aminotransferase (U/L)	31	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (18-55 years)	MALE	34	-1	-4	Alkaline Phosphatase (U/L)	71	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (18-55 years)	MALE	34	1	1	Alkaline Phosphatase (U/L)	91	N/A	N/A	N/A	N/A

Appendix E (continued)
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
(b) (6)	100 mcg mRNA-1273 (18-55 years)	MALE	34	8	8	Alkaline Phosphatase (U/L)	59	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (18-55 years)	MALE	34	29	29	Alkaline Phosphatase (U/L)	73	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (18-55 years)	MALE	34	36	36	Alkaline Phosphatase (U/L)	64	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (18-55 years)	MALE	34	-1	-4	Aspartate Aminotransferase (U/L)	23	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (18-55 years)	MALE	34	1	1	Aspartate Aminotransferase (U/L)	29	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (18-55 years)	MALE	34	8	8	Aspartate Aminotransferase (U/L)	41	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (18-55 years)	MALE	34	29	29	Aspartate Aminotransferase (U/L)	20	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (18-55 years)	MALE	34	36	36	Aspartate Aminotransferase (U/L)	20	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (18-55 years)	MALE	34	-1	-4	Creatinine (mg/dL)	1.18	N/A	N/A	N/A	N/A

Appendix E (continued)
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
(b) (6)	100 mcg mRNA-1273 (18-55 years)	MALE	34	1	1	Creatinine (mg/dL)	1.17	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (18-55 years)	MALE	34	8	8	Creatinine (mg/dL)	1.20	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (18-55 years)	MALE	34	29	29	Creatinine (mg/dL)	1.14	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (18-55 years)	MALE	34	36	36	Creatinine (mg/dL)	1.26	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (18-55 years)	MALE	34	-1	-4	Hemoglobin (g/dL)	15.1	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (18-55 years)	MALE	34	1	1	Hemoglobin (g/dL)	13.1 (Mild)	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (18-55 years)	MALE	34	8	8	Hemoglobin (g/dL)	14.2	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (18-55 years)	MALE	34	29	29	Hemoglobin (g/dL)	14.0	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (18-55 years)	MALE	34	36	36	Hemoglobin (g/dL)	14.3	N/A	N/A	N/A	N/A

Appendix E (continued)
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
(b) (6)	100 mcg mRNA-1273 (18-55 years)	MALE	34	8	8	Serum Lipase (U/L)	18.0	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (18-55 years)	MALE	34	29	29	Serum Lipase (U/L)	41.0	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (18-55 years)	MALE	34	36	36	Serum Lipase (U/L)	21.0	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (18-55 years)	MALE	34	-1	-4	Total Bilirubin (mg/dL)	0.9	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (18-55 years)	MALE	34	1	1	Total Bilirubin (mg/dL)	0.8	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (18-55 years)	MALE	34	8	8	Total Bilirubin (mg/dL)	1.2	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (18-55 years)	MALE	34	29	29	Total Bilirubin (mg/dL)	0.9	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (18-55 years)	MALE	34	36	36	Total Bilirubin (mg/dL)	1.0	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (18-55 years)	MALE	34	-1	-4	WBC (10 ³ /uL)	8.2	N/A	N/A	N/A	N/A

Appendix E (continued)
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
(b) (6)	100 mcg mRNA-1273 (18-55 years)	MALE	32	-1	-3	Alkaline Phosphatase (U/L)	49	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (18-55 years)	MALE	32	1	1	Alkaline Phosphatase (U/L)	42	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (18-55 years)	MALE	32	8	8	Alkaline Phosphatase (U/L)	47	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (18-55 years)	MALE	32	29	28	Alkaline Phosphatase (U/L)	35	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (18-55 years)	MALE	32	36	35	Alkaline Phosphatase (U/L)	39	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (18-55 years)	MALE	32	-1	-3	Aspartate Aminotransferase (U/L)	17	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (18-55 years)	MALE	32	1	1	Aspartate Aminotransferase (U/L)	18	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (18-55 years)	MALE	32	8	8	Aspartate Aminotransferase (U/L)	14	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (18-55 years)	MALE	32	29	28	Aspartate Aminotransferase (U/L)	16	N/A	N/A	N/A	N/A

Appendix E (continued)
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
(b) (6)	100 mcg mRNA-1273 (18-55 years)	MALE	32	36	35	Total Bilirubin (mg/dL)	0.6	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (18-55 years)	MALE	32	-1	-3	WBC (10 ³ /uL)	6.3	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (18-55 years)	MALE	32	1	1	WBC (10 ³ /uL)	4.7	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (18-55 years)	MALE	32	8	8	WBC (10 ³ /uL)	4.6	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (18-55 years)	MALE	32	29	28	WBC (10 ³ /uL)	4.9	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (18-55 years)	MALE	32	36	35	WBC (10 ³ /uL)	5.1	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (18-55 years)	FEMALE	26	-1	-5	Alanine Aminotransferase (U/L)	10	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (18-55 years)	FEMALE	26	1	1	Alanine Aminotransferase (U/L)	11	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (18-55 years)	FEMALE	26	8	8	Alanine Aminotransferase (U/L)	12	N/A	N/A	N/A	N/A

Appendix E (continued)
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
(b) (6)	100 mcg mRNA-1273 (18-55 years)	FEMALE	26	29	29	Alanine Aminotransferase (U/L)	9	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (18-55 years)	FEMALE	26	36	36	Alanine Aminotransferase (U/L)	11	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (18-55 years)	FEMALE	26	-1	-5	Alkaline Phosphatase (U/L)	45	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (18-55 years)	FEMALE	26	1	1	Alkaline Phosphatase (U/L)	43	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (18-55 years)	FEMALE	26	8	8	Alkaline Phosphatase (U/L)	42	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (18-55 years)	FEMALE	26	29	29	Alkaline Phosphatase (U/L)	45	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (18-55 years)	FEMALE	26	36	36	Alkaline Phosphatase (U/L)	46	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (18-55 years)	FEMALE	26	-1	-5	Aspartate Aminotransferase (U/L)	14	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (18-55 years)	FEMALE	26	1	1	Aspartate Aminotransferase (U/L)	14	N/A	N/A	N/A	N/A

Appendix E (continued)
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
(b) (6)	100 mcg mRNA-1273 (18-55 years)	FEMALE	26	8	8	Aspartate Aminotransferase (U/L)	17	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (18-55 years)	FEMALE	26	29	29	Aspartate Aminotransferase (U/L)	13	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (18-55 years)	FEMALE	26	36	36	Aspartate Aminotransferase (U/L)	16	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (18-55 years)	FEMALE	26	-1	-5	Creatinine (mg/dL)	0.69	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (18-55 years)	FEMALE	26	1	1	Creatinine (mg/dL)	0.64	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (18-55 years)	FEMALE	26	8	8	Creatinine (mg/dL)	0.65	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (18-55 years)	FEMALE	26	29	29	Creatinine (mg/dL)	0.64	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (18-55 years)	FEMALE	26	36	36	Creatinine (mg/dL)	0.75	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (18-55 years)	FEMALE	26	-1	-5	Hemoglobin (g/dL)	14.1	N/A	N/A	N/A	N/A

Appendix E (continued)
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
(b) (6)	100 mcg mRNA-1273 (18-55 years)	FEMALE	26	1	1	Hemoglobin (g/dL)	13.4	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (18-55 years)	FEMALE	26	8	8	Hemoglobin (g/dL)	12.4 (Mild)	NOT RELATED	phlebotomy	NC- DOSE NOT CHANGED	No
	100 mcg mRNA-1273 (18-55 years)	FEMALE	26	29	29	Hemoglobin (g/dL)	12.1 (Mild)	NOT RELATED	Normal variation	NC- DOSE NOT CHANGED	No
	100 mcg mRNA-1273 (18-55 years)	FEMALE	26	36	36	Hemoglobin (g/dL)	13.0 (Mild)	NOT RELATED	normal lab variation	NA-NOT APPLICABLE	No
	100 mcg mRNA-1273 (18-55 years)	FEMALE	26	-1	-5	PT (seconds)	11.0	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (18-55 years)	FEMALE	26	-1	-5	PTT (seconds)	30	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (18-55 years)	FEMALE	26	-1	-5	Platelets (10 ³ /uL)	247	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (18-55 years)	FEMALE	26	1	1	Platelets (10 ³ /uL)	222	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (18-55 years)	FEMALE	26	8	8	Platelets (10 ³ /uL)	217	N/A	N/A	N/A	N/A

Appendix E (continued)
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
(b) (6)	100 mcg mRNA-1273 (18-55 years)	FEMALE	26	29	29	Platelets (10 ³ /uL)	211	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (18-55 years)	FEMALE	26	36	36	Platelets (10 ³ /uL)	249	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (18-55 years)	FEMALE	26	-1	-5	Serum Lipase (U/L)	12.0	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (18-55 years)	FEMALE	26	1	1	Serum Lipase (U/L)	10.0	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (18-55 years)	FEMALE	26	8	8	Serum Lipase (U/L)	12.0	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (18-55 years)	FEMALE	26	29	29	Serum Lipase (U/L)	14.0	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (18-55 years)	FEMALE	26	36	36	Serum Lipase (U/L)	15.0	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (18-55 years)	FEMALE	26	-1	-5	Total Bilirubin (mg/dL)	0.8	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (18-55 years)	FEMALE	26	1	1	Total Bilirubin (mg/dL)	0.7	N/A	N/A	N/A	N/A

Appendix E (continued)
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
(b) (6)	100 mcg mRNA-1273 (18-55 years)	FEMALE	26	8	8	Total Bilirubin (mg/dL)	0.7	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (18-55 years)	FEMALE	26	29	29	Total Bilirubin (mg/dL)	0.6	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (18-55 years)	FEMALE	26	36	36	Total Bilirubin (mg/dL)	0.7	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (18-55 years)	FEMALE	26	-1	-5	WBC (10 ³ /uL)	5.1	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (18-55 years)	FEMALE	26	1	1	WBC (10 ³ /uL)	5.1	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (18-55 years)	FEMALE	26	8	8	WBC (10 ³ /uL)	4.2	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (18-55 years)	FEMALE	26	29	29	WBC (10 ³ /uL)	5.5	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (18-55 years)	FEMALE	26	36	36	WBC (10 ³ /uL)	4.7	N/A	N/A	N/A	N/A
	250 mcg mRNA-1273 (18-55 years)	FEMALE	41	-1	-15	Alanine Aminotransferase (U/L)	7	N/A	N/A	N/A	N/A

Appendix E (continued)
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
(b) (6)	250 mcg mRNA-1273 (18-55 years)	FEMALE	41	1	1	Alanine Aminotransferase (U/L)	7	N/A	N/A	N/A	N/A
	250 mcg mRNA-1273 (18-55 years)	FEMALE	41	8	7	Alanine Aminotransferase (U/L)	7	N/A	N/A	N/A	N/A
	250 mcg mRNA-1273 (18-55 years)	FEMALE	41	29	29	Alanine Aminotransferase (U/L)	7	N/A	N/A	N/A	N/A
	250 mcg mRNA-1273 (18-55 years)	FEMALE	41	36	36	Alanine Aminotransferase (U/L)	9	N/A	N/A	N/A	N/A
	250 mcg mRNA-1273 (18-55 years)	FEMALE	41	-1	-15	Alkaline Phosphatase (U/L)	50	N/A	N/A	N/A	N/A
	250 mcg mRNA-1273 (18-55 years)	FEMALE	41	1	1	Alkaline Phosphatase (U/L)	47	N/A	N/A	N/A	N/A
	250 mcg mRNA-1273 (18-55 years)	FEMALE	41	8	7	Alkaline Phosphatase (U/L)	53	N/A	N/A	N/A	N/A
	250 mcg mRNA-1273 (18-55 years)	FEMALE	41	29	29	Alkaline Phosphatase (U/L)	51	N/A	N/A	N/A	N/A
	250 mcg mRNA-1273 (18-55 years)	FEMALE	41	36	36	Alkaline Phosphatase (U/L)	50	N/A	N/A	N/A	N/A

Appendix E (continued)
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
(b) (6)	250 mcg mRNA-1273 (18-55 years)	FEMALE	41	-1	-15	Aspartate Aminotransferase (U/L)	14	N/A	N/A	N/A	N/A
	250 mcg mRNA-1273 (18-55 years)	FEMALE	41	1	1	Aspartate Aminotransferase (U/L)	12	N/A	N/A	N/A	N/A
	250 mcg mRNA-1273 (18-55 years)	FEMALE	41	8	7	Aspartate Aminotransferase (U/L)	15	N/A	N/A	N/A	N/A
	250 mcg mRNA-1273 (18-55 years)	FEMALE	41	29	29	Aspartate Aminotransferase (U/L)	15	N/A	N/A	N/A	N/A
	250 mcg mRNA-1273 (18-55 years)	FEMALE	41	36	36	Aspartate Aminotransferase (U/L)	14	N/A	N/A	N/A	N/A
	250 mcg mRNA-1273 (18-55 years)	FEMALE	41	-1	-15	Creatinine (mg/dL)	0.72	N/A	N/A	N/A	N/A
	250 mcg mRNA-1273 (18-55 years)	FEMALE	41	1	1	Creatinine (mg/dL)	0.77	N/A	N/A	N/A	N/A
	250 mcg mRNA-1273 (18-55 years)	FEMALE	41	8	7	Creatinine (mg/dL)	0.73	N/A	N/A	N/A	N/A
	250 mcg mRNA-1273 (18-55 years)	FEMALE	41	29	29	Creatinine (mg/dL)	0.75	N/A	N/A	N/A	N/A

Appendix E (continued)
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
(b) (6)	250 mcg mRNA-1273 (18-55 years)	FEMALE	41	36	36	Creatinine (mg/dL)	0.77	N/A	N/A	N/A	N/A
	250 mcg mRNA-1273 (18-55 years)	FEMALE	41	-1	-15	Hemoglobin (g/dL)	12.3	N/A	N/A	N/A	N/A
	250 mcg mRNA-1273 (18-55 years)	FEMALE	41	1	1	Hemoglobin (g/dL)	12.0 (Mild)	N/A	N/A	N/A	N/A
	250 mcg mRNA-1273 (18-55 years)	FEMALE	41	8	7	Hemoglobin (g/dL)	12.9	N/A	N/A	N/A	N/A
	250 mcg mRNA-1273 (18-55 years)	FEMALE	41	29	29	Hemoglobin (g/dL)	12.8	N/A	N/A	N/A	N/A
	250 mcg mRNA-1273 (18-55 years)	FEMALE	41	36	36	Hemoglobin (g/dL)	12.3	N/A	N/A	N/A	N/A
	250 mcg mRNA-1273 (18-55 years)	FEMALE	41	-1	-15	PT (seconds)	10.4	N/A	N/A	N/A	N/A
	250 mcg mRNA-1273 (18-55 years)	FEMALE	41	-1	-15	PTT (seconds)	29	N/A	N/A	N/A	N/A
	250 mcg mRNA-1273 (18-55 years)	FEMALE	41	-1	-15	Platelets (10 ³ /uL)	354	N/A	N/A	N/A	N/A

Appendix E (continued)
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
(b) (6)	250 mcg mRNA-1273 (18-55 years)	FEMALE	41	-1	-15	Total Bilirubin (mg/dL)	0.9	N/A	N/A	N/A	N/A
	250 mcg mRNA-1273 (18-55 years)	FEMALE	41	1	1	Total Bilirubin (mg/dL)	0.6	N/A	N/A	N/A	N/A
	250 mcg mRNA-1273 (18-55 years)	FEMALE	41	8	7	Total Bilirubin (mg/dL)	0.8	N/A	N/A	N/A	N/A
	250 mcg mRNA-1273 (18-55 years)	FEMALE	41	29	29	Total Bilirubin (mg/dL)	0.7	N/A	N/A	N/A	N/A
	250 mcg mRNA-1273 (18-55 years)	FEMALE	41	36	36	Total Bilirubin (mg/dL)	0.7	N/A	N/A	N/A	N/A
	250 mcg mRNA-1273 (18-55 years)	FEMALE	41	-1	-15	WBC (10 ³ /uL)	6.3	N/A	N/A	N/A	N/A
	250 mcg mRNA-1273 (18-55 years)	FEMALE	41	1	1	WBC (10 ³ /uL)	5.1	N/A	N/A	N/A	N/A
	250 mcg mRNA-1273 (18-55 years)	FEMALE	41	8	7	WBC (10 ³ /uL)	6.1	N/A	N/A	N/A	N/A
	250 mcg mRNA-1273 (18-55 years)	FEMALE	41	29	29	WBC (10 ³ /uL)	5.6	N/A	N/A	N/A	N/A

Appendix E (continued)
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
(b) (6)	250 mcg mRNA-1273 (18-55 years)	FEMALE	34	29	29	Alkaline Phosphatase (U/L)	47	N/A	N/A	N/A	N/A
	250 mcg mRNA-1273 (18-55 years)	FEMALE	34	36	36	Alkaline Phosphatase (U/L)	46	N/A	N/A	N/A	N/A
	250 mcg mRNA-1273 (18-55 years)	FEMALE	34	-1	-15	Aspartate Aminotransferase (U/L)	18	N/A	N/A	N/A	N/A
	250 mcg mRNA-1273 (18-55 years)	FEMALE	34	1	1	Aspartate Aminotransferase (U/L)	13	N/A	N/A	N/A	N/A
	250 mcg mRNA-1273 (18-55 years)	FEMALE	34	8	8	Aspartate Aminotransferase (U/L)	13	N/A	N/A	N/A	N/A
	250 mcg mRNA-1273 (18-55 years)	FEMALE	34	29	29	Aspartate Aminotransferase (U/L)	14	N/A	N/A	N/A	N/A
	250 mcg mRNA-1273 (18-55 years)	FEMALE	34	36	36	Aspartate Aminotransferase (U/L)	15	N/A	N/A	N/A	N/A
	250 mcg mRNA-1273 (18-55 years)	FEMALE	34	-1	-15	Creatinine (mg/dL)	0.97	N/A	N/A	N/A	N/A
	250 mcg mRNA-1273 (18-55 years)	FEMALE	34	1	1	Creatinine (mg/dL)	0.93	N/A	N/A	N/A	N/A

Appendix E (continued)
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
(b) (6)	250 mcg mRNA-1273 (18-55 years)	FEMALE	34	8	8	Creatinine (mg/dL)	1.00	N/A	N/A	N/A	N/A
	250 mcg mRNA-1273 (18-55 years)	FEMALE	34	29	29	Creatinine (mg/dL)	0.81	N/A	N/A	N/A	N/A
	250 mcg mRNA-1273 (18-55 years)	FEMALE	34	36	36	Creatinine (mg/dL)	0.91	N/A	N/A	N/A	N/A
	250 mcg mRNA-1273 (18-55 years)	FEMALE	34	-1	-15	Hemoglobin (g/dL)	15.1	N/A	N/A	N/A	N/A
	250 mcg mRNA-1273 (18-55 years)	FEMALE	34	1	1	Hemoglobin (g/dL)	13.9	N/A	N/A	N/A	N/A
	250 mcg mRNA-1273 (18-55 years)	FEMALE	34	8	8	Hemoglobin (g/dL)	13.8 (Mild)	NOT RELATED	study procedures - phlebotomy	NC- DOSE NOT CHANGED	No
	250 mcg mRNA-1273 (18-55 years)	FEMALE	34	29	29	Hemoglobin (g/dL)	13.3 (Mild)	NOT RELATED	related to study procedure	NA- NOT APPLICABLE	No
	250 mcg mRNA-1273 (18-55 years)	FEMALE	34	36	36	Hemoglobin (g/dL)	13.6 (Mild)				
	250 mcg mRNA-1273 (18-55 years)	FEMALE	34	-1	-15	PT (seconds)	10.6	N/A	N/A	N/A	N/A

Appendix E (continued)
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
(b) (6)	250 mcg mRNA-1273 (18-55 years)	FEMALE	38	-1	-14	WBC (10 ³ /uL)	8.0	N/A	N/A	N/A	N/A
	250 mcg mRNA-1273 (18-55 years)	FEMALE	38	1	1	WBC (10 ³ /uL)	7.2	N/A	N/A	N/A	N/A
	250 mcg mRNA-1273 (18-55 years)	FEMALE	38	8	8	WBC (10 ³ /uL)	8.1	N/A	N/A	N/A	N/A
	250 mcg mRNA-1273 (18-55 years)	FEMALE	38	29	28	WBC (10 ³ /uL)	7.6	N/A	N/A	N/A	N/A
	250 mcg mRNA-1273 (18-55 years)	FEMALE	38	36	35	WBC (10 ³ /uL)	5.9	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (56-70 years)	FEMALE	57	-1	-2	Alanine Aminotransferase (U/L)	12	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (56-70 years)	FEMALE	57	1	1	Alanine Aminotransferase (U/L)	13	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (56-70 years)	FEMALE	57	8	7	Alanine Aminotransferase (U/L)	12	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (56-70 years)	FEMALE	57	29	29	Alanine Aminotransferase (U/L)	12	N/A	N/A	N/A	N/A

Appendix E (continued)
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
(b) (6)	25 mcg mRNA-1273 (56-70 years)	FEMALE	57	36	35	Alanine Aminotransferase (U/L)	11	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (56-70 years)	FEMALE	57	-1	-2	Alkaline Phosphatase (U/L)	75	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (56-70 years)	FEMALE	57	1	1	Alkaline Phosphatase (U/L)	76	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (56-70 years)	FEMALE	57	8	7	Alkaline Phosphatase (U/L)	71	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (56-70 years)	FEMALE	57	29	29	Alkaline Phosphatase (U/L)	71	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (56-70 years)	FEMALE	57	36	35	Alkaline Phosphatase (U/L)	73	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (56-70 years)	FEMALE	57	-1	-2	Aspartate Aminotransferase (U/L)	15	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (56-70 years)	FEMALE	57	1	1	Aspartate Aminotransferase (U/L)	13	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (56-70 years)	FEMALE	57	8	7	Aspartate Aminotransferase (U/L)	13	N/A	N/A	N/A	N/A

Appendix E (continued)
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
(b) (6)	25 mcg mRNA-1273 (56-70 years)	FEMALE	57	29	29	Aspartate Aminotransferase (U/L)	13	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (56-70 years)	FEMALE	57	36	35	Aspartate Aminotransferase (U/L)	13	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (56-70 years)	FEMALE	57	-1	-2	Creatinine (mg/dL)	0.95	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (56-70 years)	FEMALE	57	1	1	Creatinine (mg/dL)	0.97	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (56-70 years)	FEMALE	57	8	7	Creatinine (mg/dL)	0.86	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (56-70 years)	FEMALE	57	29	29	Creatinine (mg/dL)	0.86	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (56-70 years)	FEMALE	57	36	35	Creatinine (mg/dL)	0.99	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (56-70 years)	FEMALE	57	-1	-2	Hemoglobin (g/dL)	12.4	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (56-70 years)	FEMALE	57	1	1	Hemoglobin (g/dL)	13.2	N/A	N/A	N/A	N/A

Appendix E (continued)
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
(b) (6)	25 mcg mRNA-1273 (56-70 years)	FEMALE	57	36	35	Platelets (10 ³ /uL)	320	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (56-70 years)	FEMALE	57	-1	-2	Serum Lipase (U/L)	33.0	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (56-70 years)	FEMALE	57	1	1	Serum Lipase (U/L)	40.0	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (56-70 years)	FEMALE	57	8	7	Serum Lipase (U/L)	22.0	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (56-70 years)	FEMALE	57	29	29	Serum Lipase (U/L)	35.0	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (56-70 years)	FEMALE	57	36	35	Serum Lipase (U/L)	29.0	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (56-70 years)	FEMALE	57	-1	-2	Total Bilirubin (mg/dL)	0.3	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (56-70 years)	FEMALE	57	1	1	Total Bilirubin (mg/dL)	0.3	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (56-70 years)	FEMALE	57	8	7	Total Bilirubin (mg/dL)	0.5	N/A	N/A	N/A	N/A

Appendix E (continued)
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
(b) (6)	25 mcg mRNA-1273 (56-70 years)	FEMALE	57	29	29	Total Bilirubin (mg/dL)	0.3	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (56-70 years)	FEMALE	57	36	35	Total Bilirubin (mg/dL)	0.3	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (56-70 years)	FEMALE	57	-1	-2	WBC (10 ³ /uL)	7.5	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (56-70 years)	FEMALE	57	1	1	WBC (10 ³ /uL)	6.2	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (56-70 years)	FEMALE	57	8	7	WBC (10 ³ /uL)	5.5	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (56-70 years)	FEMALE	57	29	29	WBC (10 ³ /uL)	8.0	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (56-70 years)	FEMALE	57	36	35	WBC (10 ³ /uL)	4.9	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (56-70 years)	FEMALE	69	-1	-2	Alanine Aminotransferase (U/L)	24	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (56-70 years)	FEMALE	69	1	1	Alanine Aminotransferase (U/L)	23	N/A	N/A	N/A	N/A

Appendix E (continued)
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
(b) (6)	25 mcg mRNA-1273 (56-70 years)	FEMALE	69	1	1	Aspartate Aminotransferase (U/L)	25	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (56-70 years)	FEMALE	69	8	8	Aspartate Aminotransferase (U/L)	22	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (56-70 years)	FEMALE	69	29	29	Aspartate Aminotransferase (U/L)	25	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (56-70 years)	FEMALE	69	36	36	Aspartate Aminotransferase (U/L)	23	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (56-70 years)	FEMALE	69	-1	-2	Creatinine (mg/dL)	0.94	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (56-70 years)	FEMALE	69	1	1	Creatinine (mg/dL)	0.91	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (56-70 years)	FEMALE	69	8	8	Creatinine (mg/dL)	0.88	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (56-70 years)	FEMALE	69	29	29	Creatinine (mg/dL)	0.95	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (56-70 years)	FEMALE	69	36	36	Creatinine (mg/dL)	0.94	N/A	N/A	N/A	N/A

Appendix E (continued)
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
(b) (6)	25 mcg mRNA-1273 (56-70 years)	FEMALE	69	-1	-2	Hemoglobin (g/dL)	14.5	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (56-70 years)	FEMALE	69	1	1	Hemoglobin (g/dL)	14.8	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (56-70 years)	FEMALE	69	8	8	Hemoglobin (g/dL)	13.6 (Mild)	NOT RELATED	study procedure (phlebotomy)	NC- DOSE NOT CHANGED	No
	25 mcg mRNA-1273 (56-70 years)	FEMALE	69	29	29	Hemoglobin (g/dL)	15.5	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (56-70 years)	FEMALE	69	36	36	Hemoglobin (g/dL)	14.8	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (56-70 years)	FEMALE	69	-1	-2	PT (seconds)	10.3	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (56-70 years)	FEMALE	69	-1	-2	PTT (seconds)	28	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (56-70 years)	FEMALE	69	-1	-2	Platelets (10 ³ /uL)	173	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (56-70 years)	FEMALE	69	1	1	Platelets (10 ³ /uL)	180	N/A	N/A	N/A	N/A

Appendix E (continued)
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
(b) (6)	25 mcg mRNA-1273 (56-70 years)	FEMALE	69	8	8	Platelets (10 ³ /uL)	159	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (56-70 years)	FEMALE	69	29	29	Platelets (10 ³ /uL)	180	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (56-70 years)	FEMALE	69	36	36	Platelets (10 ³ /uL)	188	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (56-70 years)	FEMALE	69	-1	-2	Serum Lipase (U/L)	60.0	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (56-70 years)	FEMALE	69	1	1	Serum Lipase (U/L)	67.0	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (56-70 years)	FEMALE	69	8	8	Serum Lipase (U/L)	54.0	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (56-70 years)	FEMALE	69	29	29	Serum Lipase (U/L)	62.0	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (56-70 years)	FEMALE	69	36	36	Serum Lipase (U/L)	43.0	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (56-70 years)	FEMALE	69	-1	-2	Total Bilirubin (mg/dL)	1.1	N/A	N/A	N/A	N/A

Appendix E (continued)
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
(b) (6)	100 mcg mRNA-1273 (56-70 years)	MALE	65	8	8	Hemoglobin (g/dL)	15.0 (Mild)	NOT RELATED	Phlebotomy	NC- DOSE NOT CHANGED	No
	100 mcg mRNA-1273 (56-70 years)	MALE	65	29	29	Hemoglobin (g/dL)	15.4 (Mild)				
	100 mcg mRNA-1273 (56-70 years)	MALE	65	-1	-6	PT (seconds)	10.6	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (56-70 years)	MALE	65	-1	-6	PTT (seconds)	30	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (56-70 years)	MALE	65	-1	-6	Platelets (10 ³ /uL)	232	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (56-70 years)	MALE	65	1	1	Platelets (10 ³ /uL)	226	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (56-70 years)	MALE	65	8	8	Platelets (10 ³ /uL)	215	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (56-70 years)	MALE	65	29	29	Platelets (10 ³ /uL)	217	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (56-70 years)	MALE	65	-1	-6	Serum Lipase (U/L)	24.0	N/A	N/A	N/A	N/A

Appendix E (continued)
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
(b) (6)	25 mcg mRNA-1273 (56-70 years)	MALE	65	1	1	Alkaline Phosphatase (U/L)	62	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (56-70 years)	MALE	65	8	8	Alkaline Phosphatase (U/L)	58	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (56-70 years)	MALE	65	29	29	Alkaline Phosphatase (U/L)	54	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (56-70 years)	MALE	65	-1	-5	Aspartate Aminotransferase (U/L)	30	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (56-70 years)	MALE	65	1	1	Aspartate Aminotransferase (U/L)	24	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (56-70 years)	MALE	65	8	8	Aspartate Aminotransferase (U/L)	24	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (56-70 years)	MALE	65	29	29	Aspartate Aminotransferase (U/L)	19	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (56-70 years)	MALE	65	-1	-5	Creatinine (mg/dL)	1.01	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (56-70 years)	MALE	65	1	1	Creatinine (mg/dL)	1.12	N/A	N/A	N/A	N/A

Appendix E (continued)
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
(b) (6)	25 mcg mRNA-1273 (56-70 years)	MALE	65	1	1	Platelets (10 ³ /uL)	312	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (56-70 years)	MALE	65	8	8	Platelets (10 ³ /uL)	273	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (56-70 years)	MALE	65	29	29	Platelets (10 ³ /uL)	271	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (56-70 years)	MALE	65	-1	-5	Serum Lipase (U/L)	41.0	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (56-70 years)	MALE	65	1	1	Serum Lipase (U/L)	41.0	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (56-70 years)	MALE	65	8	8	Serum Lipase (U/L)	44.0	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (56-70 years)	MALE	65	29	29	Serum Lipase (U/L)	39.0	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (56-70 years)	MALE	65	-1	-5	Total Bilirubin (mg/dL)	0.6	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (56-70 years)	MALE	65	1	1	Total Bilirubin (mg/dL)	0.5	N/A	N/A	N/A	N/A

Appendix E (continued)
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
(b) (6)	25 mcg mRNA-1273 (56-70 years)	MALE	65	8	8	Total Bilirubin (mg/dL)	0.8	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (56-70 years)	MALE	65	29	29	Total Bilirubin (mg/dL)	0.5	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (56-70 years)	MALE	65	-1	-5	WBC (10 ³ /uL)	6.5	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (56-70 years)	MALE	65	1	1	WBC (10 ³ /uL)	5.9	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (56-70 years)	MALE	65	8	8	WBC (10 ³ /uL)	6.8	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (56-70 years)	MALE	65	29	29	WBC (10 ³ /uL)	6.3	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (56-70 years)	FEMALE	58	-1	-5	Alanine Aminotransferase (U/L)	12	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (56-70 years)	FEMALE	58	1	1	Alanine Aminotransferase (U/L)	12	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (56-70 years)	FEMALE	58	8	8	Alanine Aminotransferase (U/L)	12	N/A	N/A	N/A	N/A

Appendix E (continued)
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
(b) (6)	100 mcg mRNA-1273 (56-70 years)	FEMALE	58	29	30	Alanine Aminotransferase (U/L)	14	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (56-70 years)	FEMALE	58	-1	-5	Alkaline Phosphatase (U/L)	59	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (56-70 years)	FEMALE	58	1	1	Alkaline Phosphatase (U/L)	57	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (56-70 years)	FEMALE	58	8	8	Alkaline Phosphatase (U/L)	55	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (56-70 years)	FEMALE	58	29	30	Alkaline Phosphatase (U/L)	52	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (56-70 years)	FEMALE	58	-1	-5	Aspartate Aminotransferase (U/L)	19	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (56-70 years)	FEMALE	58	1	1	Aspartate Aminotransferase (U/L)	19	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (56-70 years)	FEMALE	58	8	8	Aspartate Aminotransferase (U/L)	20	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (56-70 years)	FEMALE	58	29	30	Aspartate Aminotransferase (U/L)	20	N/A	N/A	N/A	N/A

Appendix E (continued)
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
(b) (6)	100 mcg mRNA-1273 (56-70 years)	FEMALE	58	-1	-5	Creatinine (mg/dL)	0.58	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (56-70 years)	FEMALE	58	1	1	Creatinine (mg/dL)	0.60	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (56-70 years)	FEMALE	58	8	8	Creatinine (mg/dL)	0.56	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (56-70 years)	FEMALE	58	29	30	Creatinine (mg/dL)	0.56	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (56-70 years)	FEMALE	58	-1	-5	Hemoglobin (g/dL)	13.0	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (56-70 years)	FEMALE	58	1	1	Hemoglobin (g/dL)	13.7	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (56-70 years)	FEMALE	58	8	8	Hemoglobin (g/dL)	12.8 (Mild)	NOT RELATED	Large volume phlebotomy at V01	NC- DOSE NOT CHANGED	No
	100 mcg mRNA-1273 (56-70 years)	FEMALE	58	29	30	Hemoglobin (g/dL)	12.3 (Mild)				
	100 mcg mRNA-1273 (56-70 years)	FEMALE	58	-1	-5	PT (seconds)	10.2	N/A	N/A	N/A	N/A

Appendix E (continued)
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
(b) (6)	100 mcg mRNA-1273 (56-70 years)	FEMALE	58	-1	-5	PTT (seconds)	30	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (56-70 years)	FEMALE	58	-1	-5	Platelets (10 ³ /uL)	310	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (56-70 years)	FEMALE	58	1	1	Platelets (10 ³ /uL)	320	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (56-70 years)	FEMALE	58	8	8	Platelets (10 ³ /uL)	316	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (56-70 years)	FEMALE	58	29	30	Platelets (10 ³ /uL)	287	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (56-70 years)	FEMALE	58	-1	-5	Serum Lipase (U/L)	35.0	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (56-70 years)	FEMALE	58	1	1	Serum Lipase (U/L)	33.0	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (56-70 years)	FEMALE	58	8	8	Serum Lipase (U/L)	20.0	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (56-70 years)	FEMALE	58	29	30	Serum Lipase (U/L)	23.0	N/A	N/A	N/A	N/A

Appendix E (continued)
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
(b) (6)	100 mcg mRNA-1273 (56-70 years)	FEMALE	58	-1	-5	Total Bilirubin (mg/dL)	0.4	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (56-70 years)	FEMALE	58	1	1	Total Bilirubin (mg/dL)	0.3	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (56-70 years)	FEMALE	58	8	8	Total Bilirubin (mg/dL)	0.3	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (56-70 years)	FEMALE	58	29	30	Total Bilirubin (mg/dL)	0.3	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (56-70 years)	FEMALE	58	-1	-5	WBC (10 ³ /uL)	8.0	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (56-70 years)	FEMALE	58	1	1	WBC (10 ³ /uL)	7.4	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (56-70 years)	FEMALE	58	8	8	WBC (10 ³ /uL)	5.2	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (56-70 years)	FEMALE	58	29	30	WBC (10 ³ /uL)	5.1	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (56-70 years)	MALE	66	-1	-5	Alanine Aminotransferase (U/L)	15	N/A	N/A	N/A	N/A

Appendix E (continued)
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
(b) (6)	25 mcg mRNA-1273 (56-70 years)	MALE	66	8	8	Aspartate Aminotransferase (U/L)	16	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (56-70 years)	MALE	66	29	29	Aspartate Aminotransferase (U/L)	18	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (56-70 years)	MALE	66	-1	-5	Creatinine (mg/dL)	0.92	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (56-70 years)	MALE	66	1	1	Creatinine (mg/dL)	0.87	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (56-70 years)	MALE	66	8	8	Creatinine (mg/dL)	0.93	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (56-70 years)	MALE	66	29	29	Creatinine (mg/dL)	0.93	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (56-70 years)	MALE	66	-1	-5	Hemoglobin (g/dL)	14.5	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (56-70 years)	MALE	66	1	1	Hemoglobin (g/dL)	15.2	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (56-70 years)	MALE	66	8	8	Hemoglobin (g/dL)	13.6 (Moderate)	NOT RELATED	Large volume phlebotomy at V01	NC- DOSE NOT CHANGED	No

Appendix E (continued)
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
(b) (6)	25 mcg mRNA-1273 (56-70 years)	MALE	66	29	29	Hemoglobin (g/dL)	14.1 (Mild)	NOT RELATED	normal variation	NC- DOSE NOT CHANGED	No
	25 mcg mRNA-1273 (56-70 years)	MALE	66	-1	-5	PT (seconds)	10.2	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (56-70 years)	MALE	66	-1	-5	PTT (seconds)	29	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (56-70 years)	MALE	66	-1	-5	Platelets (10 ³ /uL)	167	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (56-70 years)	MALE	66	1	1	Platelets (10 ³ /uL)	167	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (56-70 years)	MALE	66	8	8	Platelets (10 ³ /uL)	159	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (56-70 years)	MALE	66	29	29	Platelets (10 ³ /uL)	163	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (56-70 years)	MALE	66	-1	-5	Serum Lipase (U/L)	32.0	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (56-70 years)	MALE	66	1	1	Serum Lipase (U/L)	25.0	N/A	N/A	N/A	N/A

Appendix E (continued)
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
(b) (6)	25 mcg mRNA-1273 (56-70 years)	MALE	66	8	8	Serum Lipase (U/L)	25.0	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (56-70 years)	MALE	66	29	29	Serum Lipase (U/L)	30.0	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (56-70 years)	MALE	66	-1	-5	Total Bilirubin (mg/dL)	0.4	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (56-70 years)	MALE	66	1	1	Total Bilirubin (mg/dL)	0.5	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (56-70 years)	MALE	66	8	8	Total Bilirubin (mg/dL)	0.6	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (56-70 years)	MALE	66	29	29	Total Bilirubin (mg/dL)	0.5	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (56-70 years)	MALE	66	-1	-5	WBC (10 ³ /uL)	5.5	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (56-70 years)	MALE	66	1	1	WBC (10 ³ /uL)	5.4	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (56-70 years)	MALE	66	8	8	WBC (10 ³ /uL)	5.7	N/A	N/A	N/A	N/A

Appendix E (continued)
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
(b) (6)	100 mcg mRNA-1273 (56-70 years)	FEMALE	61	29	29	Alkaline Phosphatase (U/L)	42	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (56-70 years)	FEMALE	61	-1	-6	Aspartate Aminotransferase (U/L)	26	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (56-70 years)	FEMALE	61	1	1	Aspartate Aminotransferase (U/L)	25	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (56-70 years)	FEMALE	61	8	8	Aspartate Aminotransferase (U/L)	21	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (56-70 years)	FEMALE	61	29	29	Aspartate Aminotransferase (U/L)	31	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (56-70 years)	FEMALE	61	-1	-6	Creatinine (mg/dL)	0.74	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (56-70 years)	FEMALE	61	1	1	Creatinine (mg/dL)	0.67	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (56-70 years)	FEMALE	61	8	8	Creatinine (mg/dL)	0.77	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (56-70 years)	FEMALE	61	29	29	Creatinine (mg/dL)	0.75	N/A	N/A	N/A	N/A

Appendix E (continued)
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
(b) (6)	100 mcg mRNA-1273 (56-70 years)	FEMALE	61	-1	-6	Hemoglobin (g/dL)	14.3	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (56-70 years)	FEMALE	61	1	1	Hemoglobin (g/dL)	14.3	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (56-70 years)	FEMALE	61	8	8	Hemoglobin (g/dL)	13.5 (Mild)	NOT RELATED	Phlebotomy	NC- DOSE NOT CHANGED	No
	100 mcg mRNA-1273 (56-70 years)	FEMALE	61	29	29	Hemoglobin (g/dL)	14.1 (Mild)	NOT RELATED	normal variation	NA-NOT APPLICABLE	No
	100 mcg mRNA-1273 (56-70 years)	FEMALE	61	-1	-6	PT (seconds)	10.7	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (56-70 years)	FEMALE	61	-1	-6	PTT (seconds)	29	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (56-70 years)	FEMALE	61	-1	-6	Platelets (10 ³ /uL)	287	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (56-70 years)	FEMALE	61	1	1	Platelets (10 ³ /uL)	284	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (56-70 years)	FEMALE	61	8	8	Platelets (10 ³ /uL)	287	N/A	N/A	N/A	N/A

Appendix E (continued)
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
(b) (6)	100 mcg mRNA-1273 (56-70 years)	FEMALE	61	-1	-6	WBC (10 ³ /uL)	4.9	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (56-70 years)	FEMALE	61	1	1	WBC (10 ³ /uL)	4.6	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (56-70 years)	FEMALE	61	8	8	WBC (10 ³ /uL)	4.4	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (56-70 years)	FEMALE	61	29	29	WBC (10 ³ /uL)	4.4	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (56-70 years)	MALE	56	-1	-5	Alanine Aminotransferase (U/L)	20	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (56-70 years)	MALE	56	1	1	Alanine Aminotransferase (U/L)	23	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (56-70 years)	MALE	56	8	9	Alanine Aminotransferase (U/L)	23	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (56-70 years)	MALE	56	29	28	Alanine Aminotransferase (U/L)	32	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (56-70 years)	MALE	56	-1	-5	Alkaline Phosphatase (U/L)	74	N/A	N/A	N/A	N/A

Appendix E (continued)
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
(b) (6)	100 mcg mRNA-1273 (56-70 years)	MALE	56	1	1	Alkaline Phosphatase (U/L)	66	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (56-70 years)	MALE	56	8	9	Alkaline Phosphatase (U/L)	81	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (56-70 years)	MALE	56	29	28	Alkaline Phosphatase (U/L)	78	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (56-70 years)	MALE	56	-1	-5	Aspartate Aminotransferase (U/L)	21	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (56-70 years)	MALE	56	1	1	Aspartate Aminotransferase (U/L)	27	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (56-70 years)	MALE	56	8	9	Aspartate Aminotransferase (U/L)	24	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (56-70 years)	MALE	56	29	28	Aspartate Aminotransferase (U/L)	54 (Mild)	NOT RELATED	alcohol consumption	NC- DOSE NOT CHANGED	No
	100 mcg mRNA-1273 (56-70 years)	MALE	56	-1	-5	Creatinine (mg/dL)	0.94	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (56-70 years)	MALE	56	1	1	Creatinine (mg/dL)	0.99	N/A	N/A	N/A	N/A

Appendix E (continued)
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
(b) (6)	100 mcg mRNA-1273 (56-70 years)	MALE	56	8	9	Creatinine (mg/dL)	1.01	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (56-70 years)	MALE	56	29	28	Creatinine (mg/dL)	0.96	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (56-70 years)	MALE	56	-1	-5	Hemoglobin (g/dL)	14.5	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (56-70 years)	MALE	56	1	1	Hemoglobin (g/dL)	14.0	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (56-70 years)	MALE	56	8	9	Hemoglobin (g/dL)	14.0	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (56-70 years)	MALE	56	29	28	Hemoglobin (g/dL)	13.8 (Mild)	NOT RELATED	normal variation	NC- DOSE NOT CHANGED	No
	100 mcg mRNA-1273 (56-70 years)	MALE	56	-1	-5	PT (seconds)	10.3	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (56-70 years)	MALE	56	-1	-5	PTT (seconds)	30	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (56-70 years)	MALE	56	-1	-5	Platelets (10 ³ /uL)	219	N/A	N/A	N/A	N/A

Appendix E (continued)
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
(b) (6)	100 mcg mRNA-1273 (56-70 years)	MALE	56	1	1	Platelets (10 ³ /uL)	221	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (56-70 years)	MALE	56	8	9	Platelets (10 ³ /uL)	240	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (56-70 years)	MALE	56	29	28	Platelets (10 ³ /uL)	222	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (56-70 years)	MALE	56	-1	-5	Serum Lipase (U/L)	33.0	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (56-70 years)	MALE	56	1	1	Serum Lipase (U/L)	25.0	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (56-70 years)	MALE	56	8	9	Serum Lipase (U/L)	33.0	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (56-70 years)	MALE	56	29	28	Serum Lipase (U/L)	30.0	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (56-70 years)	MALE	56	-1	-5	Total Bilirubin (mg/dL)	0.4	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (56-70 years)	MALE	56	1	1	Total Bilirubin (mg/dL)	0.5	N/A	N/A	N/A	N/A

Appendix E (continued)
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
(b) (6)	100 mcg mRNA-1273 (56-70 years)	MALE	56	8	9	Total Bilirubin (mg/dL)	0.5	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (56-70 years)	MALE	56	29	28	Total Bilirubin (mg/dL)	0.5	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (56-70 years)	MALE	56	-1	-5	WBC (10 ³ /uL)	4.6	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (56-70 years)	MALE	56	1	1	WBC (10 ³ /uL)	4.9	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (56-70 years)	MALE	56	8	9	WBC (10 ³ /uL)	4.7	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (56-70 years)	MALE	56	29	28	WBC (10 ³ /uL)	4.0	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (18-55 years)	MALE	46	-1	-11	Alanine Aminotransferase (U/L)	34	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (18-55 years)	MALE	46	1	1	Alanine Aminotransferase (U/L)	53 (Mild)	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (18-55 years)	MALE	46	8	8	Alanine Aminotransferase (U/L)	43	N/A	N/A	N/A	N/A

Appendix E (continued)
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
(b) (6)	25 mcg mRNA-1273 (18-55 years)	MALE	46	1	1	Hemoglobin (g/dL)	16.0	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (18-55 years)	MALE	46	8	8	Hemoglobin (g/dL)	16.2	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (18-55 years)	MALE	46	29	30	Hemoglobin (g/dL)	15.8 (Mild)	NOT RELATED	Study procedure	NA- NOT APPLICABLE	No
	25 mcg mRNA-1273 (18-55 years)	MALE	46	36	38	Hemoglobin (g/dL)	16.0	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (18-55 years)	MALE	46	-1	-11	PT (seconds)	10.2	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (18-55 years)	MALE	46	-1	-11	PTT (seconds)	29	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (18-55 years)	MALE	46	-1	-11	Platelets (10 ³ /uL)	264	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (18-55 years)	MALE	46	1	1	Platelets (10 ³ /uL)	186	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (18-55 years)	MALE	46	8	8	Platelets (10 ³ /uL)	225	N/A	N/A	N/A	N/A

Appendix E (continued)
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
(b) (6)	25 mcg mRNA-1273 (18-55 years)	FEMALE	25	1	1	Alanine Aminotransferase (U/L)	18	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (18-55 years)	FEMALE	25	8	8	Alanine Aminotransferase (U/L)	20	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (18-55 years)	FEMALE	25	29	30	Alanine Aminotransferase (U/L)	16	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (18-55 years)	FEMALE	25	36	38	Alanine Aminotransferase (U/L)	14	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (18-55 years)	FEMALE	25	-1	-10	Alkaline Phosphatase (U/L)	50	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (18-55 years)	FEMALE	25	1	1	Alkaline Phosphatase (U/L)	64	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (18-55 years)	FEMALE	25	8	8	Alkaline Phosphatase (U/L)	46	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (18-55 years)	FEMALE	25	29	30	Alkaline Phosphatase (U/L)	43	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (18-55 years)	FEMALE	25	36	38	Alkaline Phosphatase (U/L)	49	N/A	N/A	N/A	N/A

Appendix E (continued)
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
(b) (6)	25 mcg mRNA-1273 (18-55 years)	FEMALE	25	-1	-10	Aspartate Aminotransferase (U/L)	18	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (18-55 years)	FEMALE	25	1	1	Aspartate Aminotransferase (U/L)	22	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (18-55 years)	FEMALE	25	8	8	Aspartate Aminotransferase (U/L)	28	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (18-55 years)	FEMALE	25	29	30	Aspartate Aminotransferase (U/L)	18	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (18-55 years)	FEMALE	25	36	38	Aspartate Aminotransferase (U/L)	22	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (18-55 years)	FEMALE	25	-1	-10	Creatinine (mg/dL)	0.82	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (18-55 years)	FEMALE	25	1	1	Creatinine (mg/dL)	0.88	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (18-55 years)	FEMALE	25	8	8	Creatinine (mg/dL)	0.85	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (18-55 years)	FEMALE	25	29	30	Creatinine (mg/dL)	0.93	N/A	N/A	N/A	N/A

Appendix E (continued)
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
(b) (6)	25 mcg mRNA-1273 (18-55 years)	FEMALE	25	1	1	Platelets (10 ³ /uL)	270	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (18-55 years)	FEMALE	25	8	8	Platelets (10 ³ /uL)	282	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (18-55 years)	FEMALE	25	29	30	Platelets (10 ³ /uL)	290	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (18-55 years)	FEMALE	25	36	38	Platelets (10 ³ /uL)	287	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (18-55 years)	FEMALE	25	-1	-10	Serum Lipase (U/L)	60.0	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (18-55 years)	FEMALE	25	1	1	Serum Lipase (U/L)	54.0	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (18-55 years)	FEMALE	25	8	8	Serum Lipase (U/L)	46.0	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (18-55 years)	FEMALE	25	29	30	Serum Lipase (U/L)	50.0	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (18-55 years)	FEMALE	25	36	38	Serum Lipase (U/L)	48.0	N/A	N/A	N/A	N/A

Appendix E (continued)
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
(b) (6)	25 mcg mRNA-1273 (18-55 years)	FEMALE	25	-1	-10	Total Bilirubin (mg/dL)	0.9	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (18-55 years)	FEMALE	25	1	1	Total Bilirubin (mg/dL)	0.4	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (18-55 years)	FEMALE	25	8	8	Total Bilirubin (mg/dL)	0.6	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (18-55 years)	FEMALE	25	29	30	Total Bilirubin (mg/dL)	0.8	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (18-55 years)	FEMALE	25	36	38	Total Bilirubin (mg/dL)	0.6	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (18-55 years)	FEMALE	25	-1	-10	WBC (10 ³ /uL)	4.5	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (18-55 years)	FEMALE	25	1	1	WBC (10 ³ /uL)	5.0	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (18-55 years)	FEMALE	25	8	8	WBC (10 ³ /uL)	4.7	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (18-55 years)	FEMALE	25	29	30	WBC (10 ³ /uL)	3.6	N/A	N/A	N/A	N/A

Appendix E (continued)
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
(b) (6)	25 mcg mRNA-1273 (18-55 years)	FEMALE	25	36	38	WBC (10 ⁶ -{super 3}/uL)	4.4	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (18-55 years)	FEMALE	32	-1	-10	Alanine Aminotransferase (U/L)	10	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (18-55 years)	FEMALE	32	1	1	Alanine Aminotransferase (U/L)	11	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (18-55 years)	FEMALE	32	8	8	Alanine Aminotransferase (U/L)	9	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (18-55 years)	FEMALE	32	29	30	Alanine Aminotransferase (U/L)	9	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (18-55 years)	FEMALE	32	36	38	Alanine Aminotransferase (U/L)	7	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (18-55 years)	FEMALE	32	-1	-10	Alkaline Phosphatase (U/L)	41	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (18-55 years)	FEMALE	32	1	1	Alkaline Phosphatase (U/L)	45	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (18-55 years)	FEMALE	32	8	8	Alkaline Phosphatase (U/L)	34	N/A	N/A	N/A	N/A

Appendix E (continued)
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
(b) (6)	25 mcg mRNA-1273 (18-55 years)	FEMALE	32	8	8	Creatinine (mg/dL)	0.74	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (18-55 years)	FEMALE	32	29	30	Creatinine (mg/dL)	0.70	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (18-55 years)	FEMALE	32	36	38	Creatinine (mg/dL)	0.73	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (18-55 years)	FEMALE	32	-1	-10	Hemoglobin (g/dL)	12.3	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (18-55 years)	FEMALE	32	1	1	Hemoglobin (g/dL)	11.7 (Mild)	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (18-55 years)	FEMALE	32	8	8	Hemoglobin (g/dL)	11.3 (Mild)	RELATED	N/A	N/A	N/A
	25 mcg mRNA-1273 (18-55 years)	FEMALE	32	29	30	Hemoglobin (g/dL)	10.6 (Mild)	RELATED	N/A	N/A	N/A
	25 mcg mRNA-1273 (18-55 years)	FEMALE	32	36	38	Hemoglobin (g/dL)	11.2 (Mild)	RELATED	N/A	N/A	N/A
	25 mcg mRNA-1273 (18-55 years)	FEMALE	32	-1	-10	PT (seconds)	11.5 (Mild)	N/A	N/A	N/A	N/A

Appendix E (continued)
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
(b) (6)	25 mcg mRNA-1273 (18-55 years)	FEMALE	32	29	30	Serum Lipase (U/L)	29.0	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (18-55 years)	FEMALE	32	36	38	Serum Lipase (U/L)	25.0	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (18-55 years)	FEMALE	32	-1	-10	Total Bilirubin (mg/dL)	1.0	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (18-55 years)	FEMALE	32	1	1	Total Bilirubin (mg/dL)	1.2	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (18-55 years)	FEMALE	32	8	8	Total Bilirubin (mg/dL)	1.3	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (18-55 years)	FEMALE	32	29	30	Total Bilirubin (mg/dL)	1.1	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (18-55 years)	FEMALE	32	36	38	Total Bilirubin (mg/dL)	1.0	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (18-55 years)	FEMALE	32	-1	-10	WBC (10 ³ /uL)	5.4	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (18-55 years)	FEMALE	32	1	1	WBC (10 ³ /uL)	6.4	N/A	N/A	N/A	N/A

Appendix E (continued)
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
(b) (6)	25 mcg mRNA-1273 (18-55 years)	FEMALE	44	36	38	Hemoglobin (g/dL)	11.3 (Mild)	RELATED	N/A	N/A	N/A
	25 mcg mRNA-1273 (18-55 years)	FEMALE	44	-1	-10	PT (seconds)	9.7	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (18-55 years)	FEMALE	44	-1	-10	PTT (seconds)	26	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (18-55 years)	FEMALE	44	-1	-10	Platelets (10 ³ /uL)	278	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (18-55 years)	FEMALE	44	1	1	Platelets (10 ³ /uL)	317	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (18-55 years)	FEMALE	44	8	8	Platelets (10 ³ /uL)	319	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (18-55 years)	FEMALE	44	29	30	Platelets (10 ³ /uL)	295	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (18-55 years)	FEMALE	44	36	38	Platelets (10 ³ /uL)	295	N/A	N/A	N/A	N/A
	25 mcg mRNA-1273 (18-55 years)	FEMALE	44	-1	-10	Serum Lipase (U/L)	32.0	N/A	N/A	N/A	N/A

